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Fanconi anemia is a genetic bone marrow failure syndrome. The current treatment options are suboptimal and do not prevent the
eventual onset of aplastic anemia requiring bone marrow transplantation. We previously showed that resveratrol, an antioxidant and
an activator of the protein deacetylase Sirt1, enhanced hematopoiesis in Fancd2 mutant mice and improved the impaired stem cell
quiescence observed in this disease. Given that Sirt1 is important for the function of hematopoietic stem cells, we hypothesized that
Sirt1 activation may improve hematopoiesis. Indeed, Fancd2−/− mice and wild-type mice treated with the selective Sirt1 activator
SRT3025 had increased numbers of hematopoietic stem and progenitor cells, platelets and white blood cells. SRT3025 was also
protective against acetaldehyde-induced hematopoietic damage. Unlike resveratrol, however, SRT3025 did not affect stem cell
quiescence, suggesting distinct mechanisms of action. Conditional deletion of Sirt1 in hematopoietic cells did not abrogate the
beneficial effects of SRT3025, indicating that the drug did not act by directly stimulating Sirt1 in stem cells, but must be acting
indirectly via extra-hematopoietic effects. RNA-Seq transcriptome analysis revealed the down-regulation of Egr1–p21 expression,
providing a potential mechanism for improved hematopoiesis. Overall, our data indicate that SRT3025 or related compounds may be
beneficial in Fanconi anemia and other bone marrow failure syndromes.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Abbreviations: FA, Fanconi anemia; HSPC, hematopoietic stem and
progenitor cell; HSC, hematopoietic stem cell; KSL, c-Kit+Sca-1+Lin−;
CBC, complete blood count
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Fanconi anemia (FA) is a genetic disorder characterized by
bone marrow failure, myelodysplastic syndrome, and acute
myeloid leukemia. The primary cause of mortality and
morbidity is aplastic anemia (Kutler et al., 2003). Treatmentis an open access article under the CC BY-NC-ND license
131SRT3025 expands hematopoietic stem and progenitor cellswith anabolic androgens such as oxymetholone is currently
the only small molecule therapy with known benefit, but
does not completely correct the disease (Shimamura and
Alter, 2010). Hematopoietic stem cell (HSC) transplantation
is the only curative therapy available to FA patients with
marrow aplasia (Shimamura and Alter, 2010).
FA patients have fewer CD34+ cells in their bone marrow
and suffer from additional progressive loss of CD34+ cells as
they get older (Ceccaldi et al., 2011; Kelly et al., 2007). We
and others have found that Fancd2−/− mice recapitulate im-
portant hematopoietic defects characteristic of FA, including
fewer hematopoietic stem and progenitor cells (HSPCs) in
the bone marrow, reduced long-term HSC repopulating capac-
ity, and low platelet counts in peripheral blood (Parmar et al.,
2010; Zhang et al., 2010). We therefore have used this FA
murine model to test candidate compounds for therapeutic
efficacy on hematopoiesis and cancer prevention (Zhang et al.,
2008, 2010, 2014). We found that the red wine ingredient
resveratrol helped to maintain Fancd2 mutant c-Kit+Sca-1+Lin−
(KSL) cells in quiescence (Zhang et al., 2010).
Although resveratrol was initially thought to act primarily
by activating the protein deacetylase Sirt1 (Lagouge et al.,
2006), additional modes of action have been described more
recently (Pangeni et al., 2014; Park et al., 2012). Sirt1 has
been shown to be important in the function of hematopoietic
stem cells by several groups (Rimmele et al., 2014; Singh et
al., 2013). Sirt1 deletion in the blood lineages causes in-
creased DNA damage and accelerated aging of stem cells. We
therefore reasoned that pharmacological activation of Sirt1
beyond ground state levels might be beneficial in FA. Small
molecules capable of stimulating the enzymatic activities
of Sirt1 and other sirtuins have been developed and show
beneficial effects in multiple animal models (Sinclair and
Guarente, 2014). In particular, they show promise in tumor
prevention and in the treatment of metabolic syndrome
(Hubbard and Sinclair, 2014; Kabra et al., 2009; Minor et al.,
2011; Miranda et al., 2015).
In the current study, we tested whether the potent Sirt1
activator SRT3025 (Miranda et al., 2015), a molecule that is
structurally unrelated to resveratrol, could enhance hema-
topoiesis in Fancd2−/− mice.Materials and methods
Mice
Fancd2 or Fancc mutant mice and ROSA26 transgenic mice
were maintained on the 129S4 background (Friedrich and
Soriano, 1991; Houghtaling et al., 2003; Whitney et al., 1996).
Sirt1 transgenic mice with a floxed STOP cassette were
crossed with CMV-Cre mice (Jackson Labs, stock #006054) to
induce the removal of the STOP cassette (Price et al., 2012).
The resulting mouse strain (Sirt1 OE) over-expresses Sirt1 in
all tissues. Sirt1 exon 4-floxed mice and Vav1-Cre mice were
purchased from Jackson Labs (stocks #008041 and #008610)
and crossed to generate blood-specific Sirt1 knockout mice.
Both Sirt1 over-expressing mice and blood-specific knockout
mice were maintained on a pure C57BL/6J background. The
SRT3025 diet was made by mixing SRT3025 (provided by
Sirtris, a GSK company, Cambridge, MA, USA) with common
rodent diet at 3.18 g/kg diet (Research Diets Inc., NewBrunswick, NJ, USA). Oxymetholone was purchased from
Sigma (Saint Louis, MO, USA) and mixed with standard rodent
chow at 300 mg/kg diet (Bio-Serv, NJ, USA). Each diet was
administered upon weaning (3–4 weeks of age) and the
treatment continued for 6 months unless specified otherwise.
All animals were treated in accordance with the guidelines of
the Institutional Animal Care and Use Committee.Flow cytometry
Bonemarrow cells were isolated from the femora and tibiae of
the mice and stained as described previously (Zhang et al.,
2010). The KSL antibody cocktail contains anti-mouse c-Kit,
Sca-1, and lineage markers (CD3e, CD4, CD5, CD8a, B220,
Ter119, NK1.1, Mac1, Gr1).
For analysis of CD34−KSL cells, cells were stained with
FITC-conjugated anti-mouse CD34 along with the KSL anti-
body cocktail. For the analysis of CD48−CD150+CD135−CD34−
KSL cells, PE-conjugated anti-mouse CD135 and CD34 anti-
bodies were added to the KSL antibody mixture, along with
FITC-conjugated anti-mouse CD48 and Brilliant Violet 421-
conjugated anti-mouse CD150.Serial bone marrow transplantation
Bonemarrow cells were isolated from femora and tibiae of the
donor mice and mixed with competing ROSA26 bone marrow
cells for transplantation. Fancd2−/− cells were mixed with
ROSA26 cells at an 8:1 ratio, whereas Fancd2+/+ cells were
mixed with ROSA26 at a 1:1 ratio. Four million mixed cells
were used for retro-orbital injection of recipient Fancc−/−
mice lethally irradiatedwith 1200 rad of irradiation (delivered
as two split doses 4 h apart). Six months post-transplantation,
peripheral blood was collected from each recipient to
determine repopulation efficiency. Also, bone marrow cells
were isolated from three recipients per group and trans-
planted into lethally irradiated Fancc−/− mice (4 million cells
per secondary recipient). Peripheral blood was collected from
each secondary recipient twenty weeks after transplantation
to determine the secondary repopulation potential.
DNA was purified from the recipients' peripheral blood and
used for quantitative real-time PCR analysis on a LightCycler
from Roche. Each original donor's contribution to peripheral
blood was calculated. PCR primers are listed in Supplemental
Table 1.RNA-Seq
RNA was isolated from double sorted KSL cells using Trizol
reagent (Invitrogen), followed by RNAeasy Mini Kit (Qiagen).
Each sample represented total mRNA isolated from pooled
KSL cells of 4 individual mice. Three samples per condition
were processed for library construction using TruSeq RNA
Sample Preparation Kit (Illumina).
Libraries were sequenced as 51-base-length reads on an
Illumina HiSeq 2000 genome analyzer. Bowtie short read aligner
software was used to map all reads to the mouse reference
genome (version mm9) (Langmead et al., 2009). Data was
analyzed using PoissonSeq analysis package (Li et al., 2012).
132 Q.-S. Zhang et al.The RNA-Seq raw data have been deposited into GEO
gene expression database at NCBI. The accession number is
GSE60941.
Complete blood count
Blood samples were collected in EDTA-coated capillary tubes
and used for complete blood count assay on a Hemavet
950FS Multi-species Hematology System (Drew Scientific
Inc., Dallas, TX, USA).
Colony-forming unit-spleen assay
Recipient (8–12 weeks old wild-type) mice were irradiated
with a split dose of 1100 rad one day before transplantation.
Bone marrow cells from each donor mouse (40 thousand cells
for Fancd2−/− donor or 20 thousand for other donor) were
injected into each recipient mouse. 12 days after transplan-
tation, spleens were taken and fixed with Bouin's fixative
solution.
Statistical analysis
The two-tailed, unpaired student's t-test was used for
statistical analysis. A P value less than 0.05 was considered
significant.
Results
Dietary SRT3025 administration
enhances hematopoiesis
To determine whether SRT3025 can influence hematopoie-
sis, cohorts of Fancd2−/− and wild-type mice were given
either SRT3025-supplemented rodent chow or placebo for
6 months starting at 1 month of age. The dose of SRT3025
was the same as a previous rodent study reporting beneficial
effects on a metabolic syndrome from SRT3025 administra-
tion (Miranda et al., 2015). At harvest, we collected blood
samples and determined that SRT3025 concentrations in the
plasma of the treated animals ranged between 1.5 and
3.6 μM, whereas no SRT3025 was detected in the placebo
controls. Fancd2−/− mice at this age have relatively normal
hematological parameters of peripheral blood except for
lower platelet counts and higher mean corpuscular volume
(MCV) (Zhang et al., 2015), the same two phenotypes that
are common in FA patients and usually precede the onset of
cytopenia in other lineages (Shimamura and Alter, 2010). A
complete blood count (CBC) revealed that chronic SRT3025
treatment significantly increased platelet counts and white
blood cell counts (P b 0.05 in all cases, Fig. 1A) and reduced
MCV levels (P ≤ 0.01 for both genotypes, Table 1) in both
Fancd2−/− and wild-type mice. All other hematologic para-
meters remained unchanged after SRT3025 treatment for
both genotypes (Table 1). To compare the efficacy of SRT3025
with the widely used drug oxymetholone, we then performed
a 6-month administration of oxymetholone on a cohort of
Fancd2−/− and wild-type mice. The dose of oxymetholone was
chosen to be equivalent to 80% of the maximum dose for
human FA patients (Shimamura and Alter, 2010). We recentlydiscovered that, after a chronic administration of oxymetholone
at this dose for 17 months, both Fancd2−/− and wild-type
mice exhibited clearly improved hematologic parameters,
including platelet counts, red blood cell counts, hematocrit,
and hemoglobin levels, compared with the placebo-treated
controls (Zhang et al., 2015). However, the shorter 6 month
treatment was insufficient to improve these hematologic
parameters (Supplemental Table 2). These results suggest
that SRT3025 acted faster than oxymetholone to improve
hematopoiesis.
Next, we examined the bone marrow of the mice treated
with SRT3025. The bone marrow cellularity in either
Fancd2−/− or wild-type mice showed no difference between
SRT3025-treated animals and placebo-treated controls (data
not shown). However, flow cytometry analysis demonstrated
that the fractions of KSL cells, an immunophenotypically
defined HSPC population, in SRT3025-treated Fancd2−/−
mice and wild-type mice were 22.2% (P = 0.01) and 30.0%
(P b 0.0001) larger than those in their placebo-treated
controls, respectively (Figs. 1B & C).
Consistent with the increased frequencies of HSPCs in
SRT3025-treated bone marrow, the colony-forming unit-
spleen (CFU-S) assay also confirmed that SRT3025-treated
Fancd2−/− and wild-type bone marrow cells formed 48.3%
(P b 0.01) and 59.7% (P = 0.005) more macroscopic splenic
colonies than placebo-treated Fancd2−/− and wild-type
controls, respectively (Figs. 1D & E), suggesting an improve-
ment in the number and function of progenitors in SRT3025-
treated bone marrow.
One possible mechanism for HSPC expansion is an elevated
level of proliferation. To determine the impact of SRT3025 on
the rate of HSPC proliferation, we examined the cell cycle
profiles of KSL cells from SRT3025-treated mice. Hoechst
33342 staining (for DNA content) and intracellular Ki67
staining (for cycling cells, not for quiescent G0 cells) were
used in combination to measure cell cycle phases (Wilson et
al., 2008). As shown in Figs. 2A & B, the average percentages
of quiescent G0 KSL cells in SRT3025-treated Fancd2−/− and
Fancd2+/+ mice were 29.1% and 53.2%, respectively, similar to
the average G0 percentages of 28.3% and 53.0% observed in
placebo-treated Fancd2−/− and Fancd2+/+ mice, respectively.
Likewise, the average S-G2-M proportions of KSL cells showed
no significant differences between SRT3025-treated mice and
their placebo-treated controls either. These results indicate
that SRT3025 treatment did not change the cell cycle status of
HSPCs. It is, therefore, unlikely that the increase of HSPCs
after SRT3025 administration was caused by an elevated rate
of proliferation.
We then measured the number of the more primitive
CD34−KSL cells by flow cytometry and noticed that the
bone marrow cells in SRT3025-treated Fancd2−/− and
wild-type mice had 0.0071% and 0.021% CD34−KSL cells,
respectively, significantly more than the 0.0059% and
0.016% CD34−KSL cells observed in their placebo-treated
controls (Fig. 3A).
To further assess SRT3025's effect on the size of the long-
term HSC pool, we also treated a cohort of 1-month old
wild-type C57BL/6J mice for 6 months with SRT3025. We
took advantage of Slam and other markers, which are well
characterized in C57BL/6J strain background, and examined
the most primitive long-term HSC population, defined pheno-
typically as CD48−CD150+CD135−CD34−KSL cells (Fig. 3B)
Figure 1 Effects of SRT3025 on hematopoiesis. A). Peripheral blood counts in SRT3025-treated Fancd2−/− and wild-type mice
and their placebo-treated controls. n = 14–17 for each group. B). Representative flow cytometric profiles of KSL cell frequencies in
bone marrow after 6-months of SRT3025 administration. The cells were gated on PI−Lin− first. The purple box indicates KSL cell
subset. The percentages on the profiles were the average KSL cell frequencies of pooled multiple mice for each group. C). KSL
cell frequencies in the bone marrow. The KSL percentage refers to the proportion of KSL cells among all nucleated bone marrow cells,
n = 14 for either SRT3025 or placebo group of Fancd2−/− mice, and n = 10 for either SRT3025 or placebo group of Fancd2+/+
mice. D). Representative pictures of the CFU-S assay. E). Quantification of the CFU-S results. Data represent 8 donors for each group
with 2–4 recipients for each donor. For comparison purposes, all the data were normalized to 40,000 bone marrow cell input and
shown on the figure.
133SRT3025 expands hematopoietic stem and progenitor cells(Wilson et al., 2008). We found that, after 6 months of SRT3025
administration, the frequencies of CD48−CD150+CD135−CD34−
KSL cells in SRT3025-treated C57BL/6J wild-type mice were
also significantly higher than those in placebo-treated
wild-type controls (P b 0.05, Fig. 3C). Collectively, these
results demonstrate that chronic SRT3025 administration
expands the HSC and progenitor pool and improves hemato-
logical parameters in peripheral blood.SRT3025 protects Fancd2−/− mice on chronic
ethanol treatment from acetaldehyde-induced
damage to the hematopoietic systemIt has recently been shown that aldehyde toxicity in
hematopoietic stem cells contributes to stem cell depletion
in FA patients and mouse models (Garaycoechea et al., 2012;
Table 1 Complete blood counts in SRT3025-treated Fancd2−/− and Fancd2+/+ mice.
Fancd2−/− placebo Fancd2−/− SRT3025 P Fancd2+/+ placebo Fancd2+/+SRT3025 P
WBCs, ×103/μL 6.7 ± 0.5 9.0 ± 0.8 0.02 7.4 ± 0.6 10.1 ± 1.0 0.03
RBCs, ×106/μL 9.9 ± 0.1 10.1 ± 0.1 0.24 10.0 ± 0.1 10.1 ± 0.1 0.45
Hemoglobin, g/dL 15.1 ± 0.1 15.0 ± 0.1 0.52 15.0 ± 0.2 14.8 ± 0.1 0.28
Hematocrit, % 53.6 ± 0.6 54.2 ± 0.7 0.58 54.0 ± 0.7 53.6 ± 0.8 0.71
MCV, fL 54.7 ± 0.4 52.7 ± 0.5 b0.01 54.0 ± 0.3 52.8 ± 0.3 0.01
Platelets, ×103/μL 390 ± 12 435 ± 17 0.04 505 ± 22 584 ± 23 0.02
Data were pooled results from multiple mice (14–15 mice each group) and presented as mean value ± SEM. WBCs denote white blood cells;
RBCs, red blood cells; MCV, mean corpuscular volume.
Figure 2 Effects of SRT3025 on HSPC proliferation. A). Representative cell cycle profiles of KSL cells from SRT3025-treated mice
and their gender-matched placebo-treated littermate controls. Hoechst 33342 (for DNA content) and anti-mouse Ki67 (for G0/G1
discrimination) were used together to distinguish cells in the G0, G1, and S-G2-M phases of the cell cycle. The shown percentage for
each gate was the average percentage for each group of mice. B). Statistical quantification of cell cycle results for the bone marrow
KSL cells. n = 14 for either SRT3025 or placebo group of Fancd2−/− mice, and n = 10 for either SRT3025 or placebo group of Fancd2+/+
mice. NS denotes not significant.
134 Q.-S. Zhang et al.
Figure 3 Frequency and repopulating capacity of long-term HSCs after SRT3025 administration. A). CD34−KSL cell frequencies in
the bone marrow. Data were pooled results from 12 to 15 mice for each group. B). Representative flow cytometric profiles of CD48−
CD150+CD135−CD34−KSL cells. C). CD48−CD150+CD135−CD34−KSL cell frequencies in whole bone marrow from SRT3025- or
placebo-treated wild-type C57BL/6J mice (n = 8 each). Wt denotes wild-type. D). Hematopoietic effects of SRT3025 on Fancd2−/−
and wild-type mice under chronic ethanol treatment. CBC data collected after 3 months of 5% ethanol treatment. Data are pooled
results from 12 to 14 mice in each group. NS denotes not significant.
135SRT3025 expands hematopoietic stem and progenitor cellsLangevin et al., 2011). The ability of SRT3025 to expand the
HSPC pool prompted us to test whether SRT3025 adminis-
tration could help to handle aldehyde toxicity. Since
metabolism of alcohol converts ethanol to acetaldehyde as
an intermediate metabolite, we chose to use ethanol to
generate acetaldehyde in vivo. A cohort of 6-month old
Fancd2−/− and wild-type mice were given regular water or5% ethanol for 3 months. The mice were also simultaneously
treated with either SRT3025-supplemented or placebo diet.
As shown in Fig. 3D, compared with the control mice under
regular water treatment, three months of ethanol treatment
caused a significant decrease in both platelet and white
blood cell counts in Fancd2−/− mice fed with placebo diet,
while other hematologic parameters were not significantly
136 Q.-S. Zhang et al.affected. More importantly, the Fancd2−/− mice being
given ethanol and SRT3025 concurrently were able to
maintain normal hematologic parameters (Fig. 3D). These
results suggest that SRT3025 administration may offset
acetaldehyde-induced hematologic damage in Fancd2−/−
mice. In contrast to Fancd2−/− mice, wild-type mice were
not sensitive to ethanol treatment, which is generally in
line with previous reports (Langevin et al., 2011). Also, in
the absence of ethanol-induced damage, SRT3025 still
boosted both platelet and white blood cell counts in
wild-type mice, suggesting that the protective effect of
SRT3025 on the hematopoietic system was not specific to
aldehyde detoxification, probably due to the expansion of
the HSPC pool.
SRT3025 administration does not increase or impair
HSC repopulating potential
The functional properties of long-term HSCs from SRT3025-
treated mice were assessed next using an in vivo competitive
repopulation assay. As depicted in Fig. 4A, bone marrow cells
from a test donor were mixed with ROSA26Tg/O genetically
marked bone marrow (as competitors) and then transplanted
into a lethally irradiated Fancc−/− mouse. Quantitative real-
time PCR was performed 6 months post-transplantation to
evaluate each donor's contribution to the hematopoietic
repopulation in the primary recipients. After 6 month ofFigure 4 Serial transplantation experiment. A). Strategy used in t
mo denote bone marrow, irradiation, transplantation, and month, re
SRT3025- and placebo-treated mice. % chimerism refers to the perc
Fancd2−/− donors, the data represent 6–7 donors for either SRT3025 o
donors, the data represent 5 donors each group with 2–3 recipients
as mean ± SEM. C). Secondary repopulating potential of bone marro
multiple recipients (n = 5 for original placebo-treated Fancd2+/+ d
were pooled together for each experimental group.SRT3025 treatment, HSCs from SRT3025-treated mice
exhibited hematopoietic reconstitution capacities equivalent
to those from placebo-treated controls (Fig. 4B). We then
preformed serial transplantation assays, comparing the bone
marrow cells harvested from these primary recipients. Twenty
weeks after secondary transplantation, similar secondary
hematopoietic reconstitution potential was observed for
bone marrow cells originally derived from both SRT3025-
treated and placebo-treated Fancd2+/+ mice (Fig. 4C). Con-
sistent with the severely impaired HSC function in Fancd2−/−
mice, no stable chimerism (0.1% or more) was detected in
secondary recipients that received bone marrow cells origi-
nally derived from either SRT3025-treated or placebo-treated
Fancd2−/− primary donors (date not shown). These results
indicate that long term SRT3025 administration did not per-
manently increase or decrease HSC repopulating potential.
SRT3025 does not work by direct activation of Sirt1
in hematopoietic cells
The HSPC expansion effect of SRT3025 differed from our
previous observation that Sirt1 activator resveratrol did not
change the size of the HSPC pool but helped to maintain
Fancd2 mutant KSL cells in quiescence. These distinct
effects of resveratrol and SRT3025 prompted us to question
whether SRT3025 influenced hematopoiesis through the
mediation of Sirt1 activation. To answer this question, wehe in vivo competitive repopulation experiment. BM, IR, Tx, and
spectively. B). Repopulating potential of bone marrow cells from
entage of test donor-derived cells in all donor-derived cells. For
r placebo group with 3 recipients from each donor; for Fancd2+/+
from each donor. NS denotes not significant. Data are presented
w cells from SRT3025- and placebo-treated mice. Results from
onors and n = 9 for original SRT3025-treated Fancd2+/+ donors)
137SRT3025 expands hematopoietic stem and progenitor cellsutilized a Sirt1 exon 4-floxed mouse strain and Vav1-Cre
transgenic mice to generate blood tissue-specific Sirt1
conditional knockout mice (Sirt1Flox/Flox Vav1-CreTg/O), in
which the deletion of Sirt1 exon 4 is dependent on the blood
cell-specific expression of Cre recombinase driven by Vav1
promoter (Ogilvy et al., 1998). Deletion of Sirt1 Exon 4
disrupts Sirt1 catalytic activities and mimics Sirt1-null
phenotypes (Cheng et al., 2003). qPCR with exon 4-specific
primers confirmed that Sirt1 expression in bone marrow cells
from the conditional knockout mice was undetectable. We
then gave cohorts of one-month old Sirt1Flox/Flox Vav1-CreTg/O
and Sirt1+/+ Vav1-CreTg/O mice either SRT3025-supplemented
rodent chow or placebo for 6 months. At harvest, we
observed that, as compared with placebo-treated wild-type
mice, placebo-treated Sirt1Flox/Flox Vav1-CreTg/O mice had
higher KSL frequencies but similar CFU-S forming capacities in
their bone marrow cells (Fig. 5A), indicating that the absence
of Sirt1 caused an expansion of HSPC compartment but
provided no functional improvement to these cells. These
results were in agreement with the recent observation that
Sirt1 ablation promotes aberrant HSPC expansion and loss of
HSC (Rimmele et al., 2014; Singh et al., 2013). Surprisingly,
flow cytometry analysis revealed that SRT3025 administra-
tion significantly expanded KSL compartment in both Sirt1Figure 5 Effects of SRT3025 on hematopoiesis after conditional
A). Characterization of hematopoiesis in blood-specific Sirt1 knocko
mice carried the Vav1-CreTg/O driver allele. For KSL frequencies, data
donors for each group with 2 to 4 recipients for each donor. NS de
Sirt1-overexpressing transgenic mice. n = 16–17 each for KSL freq
suppressed Egr1 gene expression in wild-type KSL cells. RNA i
dehydrogenase mRNA expression. The Egr1 expression level in the
Data represents the average (±SEM) of 10 placebo-treated or 12 SRTconditional knockout mice (by 36.2%, P b 0.01) and wild-
type controls (by 37.0%, P b 0.0001) (Fig. 5A). We also
noticed an increase of CFU-S forming ability in SRT3025-
treated Sirt1 conditional knockout mice (by 64.4%, P b 0.05)
and wild-type controls (by 39.8%, P b 0.02) (Fig. 5A). Collec-
tively, these results indicate that SRT3025's beneficial effects
are not dependent on the presence of Sirt1 in blood cells
themselves.Transgenic overexpression of Sirt1 does not
phenocopy the effects of SRT3025
It is possible that SRT3025 indirectly influenced hematopoi-
esis by the activation of Sirt1 in tissues other than blood. To
further address this issue, we also utilized a Sirt1 overex-
pressing transgenic (Sirt1 OE) mouse model to investigate
the effect of global Sirt1 overexpression on hematopoiesis.
In Sirt1 OE mice, the Sirt1 gene is constitutively over-
expressed in all the tissues, i.e. 3 to 7-fold in the bone
marrow and 13 to 15-fold in the liver (data not shown).
Interestingly, we found that Sirt1 OE mice did not show a
larger KSL population and displayed similar levels of platelet
and white blood cell counts as controls (Fig. 5B).deletion of Sirt1 in blood cells or transgenic overexpression.
ut mice (Sirt1Flox/Flox) vs. unrecombined controls (Sirt1+/+). All
represent 10–18 mice for each group. CFU-S results represent 6
notes not significant. B). Characterization of hematopoiesis in
uencies; n = 20 each for compete blood counts. C). SRT3025
nput was normalized based on glyceraldehyde 3-phosphate
KSL cells of placebo-treated mice was set at 1 as a reference.
3025-treated mice.
138 Q.-S. Zhang et al.RNA-Seq transcriptome analysis reveals a possible
mechanism for SRT3025's hematopoiesis-enhancing
effect
To further investigate potential molecular mechanisms
underlying the HSPC expansion effect of SRT3025, we used
transcriptome analysis to understand the gene expression
changes in HSPCs after SRT3025 administration. KSL cells
were sorted from bone marrow cells via flow cytometry
after 3 months of SRT3025 administration on wild-type mice
and used for RNA-Seq gene expression analysis (Wang et al.,
2009). Three individual samples (each being a pooled
sample from 4 mice) were processed for each experimental
condition, with combined reads (aligned to unique RefSeq
genes) per condition in the range of 80 million. As shown in
Table 2, six genes were significantly down-regulated by
more than 1.5 fold in SRT3025-treated wild-type KSL cells,
whereas no genes were significantly up-regulated. Most
interestingly, the cell cycle regulator p21 was down-
regulated by 2.1 fold after SRT3025 administration. Moreover,
the transcription factor early growth response-1 (Egr1) known
to control p21 transcription (Choi et al., 2008; Min et al., 2008)
was also down-regulated (Supplemental Table 3). Egr1 is
enriched in HSPCs as compared with whole bone marrow cells
in our previous RNA-Seq transcriptome analysis of KSL cells
(Zhang et al., 2015) and another recent study (Min et al.,
2008). To test whether the transcriptional down-regulation of
Egr1 indeed occurs after SRT3025 administration, we per-
formed qRT-PCR on RNA samples isolated from KSL cells. As
shown in Fig. 5C, the Egr1 mRNA levels in the KSL cells of
SRT3025-treated wild-type mice were significantly lower than
those in placebo-treated controls. These results suggest that
Egr1 suppression might be the upstream event that leads to
the transcriptional down-regulation of p21 in response to
SRT3025 down-regulation.
Discussion
FA patients have fewer HSPCs and suffer from progressive
HSPC loss. Fancd2−/− mice faithfully recapitulate this pheno-
type and are born with a smaller HSPC pool. In this study, we
found that oral administration of the Sirt1 activator SRT3025
partially corrected this hematopoietic defect by expanding
the HSPC compartment. This modest expansion was shown not
only by quantitation of immunophenotypically defined stem
cells, but also functionally in the CFU-S assay. A larger stem
cell and progenitor pool could potentially lead to an increase
in peripheral blood counts of multiple lineages. Indeed, weTable 2 Genes differentially changed in wild-type HSPCs in resp
Gene Symbol
p21 Cdkn1a
Thrombospondin 1 Thbs1
Myosin light chain 2 precursor, variant 2 Myl10
Fos-like antigen 2 Fosl2
Immunoglobulin J chain Igj
Tight junction protein Magi1 Magi1
a q value represents false discovery rate. The q value cut-off was seobserved a significant increase in platelet and white blood cell
counts after only 6 months of chronic SRT3025 administration
in both Fancd2−/− and wild type mice. From a therapeutic
standpoint, the improvement of peripheral blood counts at
this early time point is rather promising. In a similarly designed
study with the same strain of FA mice, it took 17 months of
oxymetholone therapy before peripheral blood counts im-
proved (Zhang et al., 2015).
The benefits of SRT3025 on hematopoiesis were not
specific to FA. As a matter of fact, the compound had a
larger effect on both the expansion of HSPC pool and the
increase of platelet counts in wild-type mice than in
Fancd2−/− mice. This is probably due to the severe pre-
existing functional impairment of Fancd2−/− HSCs demon-
strated by multiple investigators (Garaycoechea et al.,
2012; Parmar et al., 2010; Zhang et al., 2010). Since its
efficacy is genotype independent, SRT3025 might be useful
in the treatment of bone marrow failure diseases other than
FA. For example, mutations in the checkpoint regulator Atr
cause a phenotype similar to FA with HSPC loss in mice and
humans (Seckel syndrome) (Ruzankina et al., 2007). Similar-
ly, Atm−/− mice also fail to maintain a normal stem cell
capacity (Takubo et al., 2008).
Our studies shed light on the possible mechanism(s)
behind SRT3025's actions. First, SRT3025 did not act through
the direct activation of Sirt1 in hematopoietic cells.
Conditional ablation of the Sirt1 gene in all hematopoietic
cells did not prevent the expansion of HSPC by SRT3025.
Second, constitutive and systemic transgenic overexpres-
sion of Sirt1 did not cause increases in HSPC number.
Consistently, the known Sirt1 activator resveratrol did not
change the size of the HSPC pool and had a rather distinct
effect on hematopoiesis in the same Fancd2−/− mouse
model (Zhang et al., 2010). These findings could indicate
that SRT3025 increases the stem cell pool by an off-target
effect completely unrelated to its potent Sirt1 activation in
vitro. No such off-target effects of this drug are known.
Third, the beneficial effects on hematopoiesis from SRT3025
were correlatedwith the expansion of HSPCs. The size of HSPC
population is maintained by a balance of survival, prolifera-
tion, and self-renewal (Alenzi et al., 2009). However, the
proliferation rate and repopulating potential of HSPCs were
unchanged after SRT3025 administration. In light of the recent
finding that an exacerbated p53/p21 DNA damage response
limits HSPC survival tomaintain genome integrity and suppress
tumors (Ceccaldi et al., 2012), it is possible that SRT3025
enhanced the survival of HSPCs. Finally, the transcriptome
analysis of HSPCs in SRT3025-treated mice supported this
hypothesis. SRT3025 suppressed the transcription of p21, oneonse to SRT3025 administration.
Fold change P value q value a
−2.1 b0.001 b0.001
−3.0 b0.001 b0.001
−1.8 b0.001 b0.001
−1.8 b0.001 0.044
−2.3 b0.001 0.044
−3.0 b0.001 0.044
t at 0.05. Genes are sorted according to the q values.
139SRT3025 expands hematopoietic stem and progenitor cellsof the critical p53-target genes. We showed previously that
siRNA knock-down of p21 mimicked p53 suppression and
rescued the functional defects of FA patients' CD34+ cells,
suggesting p21 as one mediator of p53-driven HSC elimination
(Ceccaldi et al., 2012). However, complete genetic ablation of
p21 in Fancd2−/− mice failed to rescue the hematopoietic
defects of Fancd2−/− mice and pointed out an indispensable
role of p21 in maintaining the normal size of the HSPC pool
(Zhang et al., 2013). While these findings appear contradic-
tory at first glance, the apparently opposite outcomes might
be explained by the difference between partial down-
regulation and complete ablation of p21 activity. Therefore,
it is possible that the transcriptional suppression of p21 by
SRT3025 contributes to the compound's beneficial effects on
hematopoiesis.
More interestingly, our data suggest that SRT3025 might
suppress p21 transcription through the down-regulation of
Egr1. Egr1 modulates p21 gene expression and also plays
important functions in HSPC development and proliferation
(Krishnaraju et al., 2001; Min et al., 2008; Ragione et al.,
2003). Within the bone marrow, Egr1 expression is highly
enriched in hematopoietic stem and progenitor cells (Min et
al., 2008; Zhang et al., 2015). Systemic deletion of Egr1 gene
in mice alters the expression of multiple genes including
Bmi-1, Cdk4, and p21, and causes enhanced HSC proliferation
and premature HSC exhaustion in serial transplantation (Min
et al., 2008). Under our experimental conditions, SRT3025-
induced Egr1 down-regulation only affected p21 gene expres-
sion and did not impair HSC secondary hematopoietic
reconstitution potential in serial transplantation. It has been
proved that lower levels of p53/p21 expression in a subset of
FA patients lead to milder bone marrow deficiency (Ceccaldi
et al., 2011). More importantly, recent work showed that the
transcriptional activation of p21 by Egr1 is independent of p53
(Choi et al., 2008). Given the detrimental tumorigenic effects
of p53 loss, SRT3025-mediated Egr1–p21 down-regulation
might be able to at least prevent the progressive HSPC
elimination in FA patients without compromising p53 activity
that is key to genome integrity. It is temping to propose that
targeting Egr1–p21 signaling might represent a new venue in
the future design of therapeutic regimens for FA patients.
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